IDH mutations in low-grade gliomas have a significantly positive effect on overall survival (hazard ratio, 0.64) with TMZ treatment [178], independent of histologic phenotype, and usually predict the presence of MGMT promoter methylation in 84% of IDH-mutant low-grade tumors [171]. This evidence concerns the gene IDH1 and glioma.